Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 8, 2007 - Issue 16
Submit an article Journal homepage
451
Views
23
CrossRef citations to date
0
Altmetric
Drug Evaluation

Apomorphine therapy in Parkinson's disease: a review

Ihtsham Ul Haq Research Fellow, Movement Disorders Program, University of Florida, Department of Neurology/McKnight Brain Institute, 100 S. Newell Drive, PO Box 100236, Gainesville, Florida 32610-0236, USA +1 352 273 5550; +1 352 273 5575; [email protected]
,
Peter A Lewitt Professor of Neurology, Wayne State University, Clinical Neuroscience Center (P.A.L.) 26400 W. 12 Mile Rd, Suite 180 Southfield, MI 48034, USA
&
Hubert H Fernandez Co Director, Movement Disorders Program, University of Florida, Department of Neurology/McKnight Brain Institute, 100 S. Newell Drive, PO Box 100236, Gainesville, Florida 32610-0236, USA +1 352 273 5550; +1 352 273 5575; [email protected]
Pages 2799-2809 | Published online: 24 Oct 2007

Citations (23)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Antonio Di Stefano, Piera Sozio, Antonio Iannitelli & Laura Serafina Cerasa. (2009) New drug delivery strategies for improved Parkinson's disease therapy. Expert Opinion on Drug Delivery 6:4, pages 389-404.
Read now

Articles from other publishers (22)

Glenardi Glenardi, Tutwuri HandayaniJimmy BarusGhea Mangkuliguna. (2022) Inhaled Levodopa (CVT-301) for the Treatment of Parkinson Disease. Neurology Clinical Practice 12:2, pages 139-148.
Crossref
Suman Gaire, Sunam Kafle, Sanjiv Bastakoti, Anuj Paudel & Kumar Karki. (2021) Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson’s Disease: A Systematic Review. Cureus.
Crossref
Federico Carbone, Atbin Djamshidian, Klaus Seppi & Werner Poewe. (2019) Apomorphine for Parkinson’s Disease: Efficacy and Safety of Current and New Formulations. CNS Drugs 33:9, pages 905-918.
Crossref
Diana Hengartner & Hubert H. Fernandez. (2019) The next chapter in symptomatic Parkinson disease treatments. Parkinsonism & Related Disorders 59, pages 39-48.
Crossref
Marianne Luinstra, Wijnand Rutgers, Teus van Laar, Floris Grasmeijer, Anja Begeman, Valmira Isufi, Luc Steenhuis, Paul Hagedoorn, Anne de Boer & Henderik W. Frijlink. (2019) Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson’s disease. Therapeutic Advances in Chronic Disease 10, pages 204062231985761.
Crossref
Mahendra K. Sreeramoju & George A. Digenis. (2018) Nucleophilic Addition in Aqueous Apomorphine Formulation Solutions in the Presence of Sodium Metabisulfite: Implications for Formulation Development and Manufacturing. Journal of Pharmaceutical Sciences 107:12, pages 3003-3006.
Crossref
Nrupa Borkar, Huiling Mu & René Holm. (2018) Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease. Asian Journal of Pharmaceutical Sciences 13:6, pages 507-517.
Crossref
Elena García-Zamora, Marta Elosua-González & Uxúa Floristán-Muruzábal. (2018) Fat necrosis and subcutaneous abscesses due to apomorphine. Medicina Clínica 151:7, pages 294-295.
Crossref
Elena García-Zamora, Marta Elosua-González & Uxúa Floristán-Muruzábal. (2018) Fat necrosis and subcutaneous abscesses due to apomorphine. Medicina Clínica (English Edition) 151:7, pages 294-295.
Crossref
Manon Auffret, Sophie Drapier & Marc Vérin. (2018) Pharmacological Insights into the Use of Apomorphine in Parkinson’s Disease: Clinical Relevance. Clinical Drug Investigation 38:4, pages 287-312.
Crossref
Ignacio RegidorVicente BenitaMarta del Álamo de PedroLuis LeyJuan Carlos Martinez Castrillo. (2017) Duodenal Levodopa Infusion for Long-Term Deep Brain Stimulation–Refractory Symptoms in Advanced Parkinson Disease. Clinical Neuropharmacology 40:3, pages 103-107.
Crossref
M. Auffret, S. Drapier, M. Vérin & P. Sauleau. (2016) Apomorphine en perfusion sous-cutanée continue dans la maladie de Parkinson : le point de vue pharmacologique. Pratique Neurologique - FMC 7:1, pages 25-32.
Crossref
S. Drapier, M. Auffret, M. Vérin & P. Sauleau. (2016) Apomorphine en perfusion sous-cutanée continue dans la maladie de Parkinson : le point de vue clinique. Pratique Neurologique - FMC 7:1, pages 33-39.
Crossref
Marianne Luinstra, Floris Grasmeijer, Paul Hagedoorn, Jan Reindert Moes, Henderik W. Frijlink & Anne H. de Boer. (2015) A levodopa dry powder inhaler for the treatment of Parkinson’s disease patients in off periods. European Journal of Pharmaceutics and Biopharmaceutics 97, pages 22-29.
Crossref
Roongroj Bhidayasiri, K. Ray Chaudhuri, Peter LeWitt, Anne Martin, Kamolwan Boonpang & Teus van Laar. (2015) Effective Delivery of Apomorphine in the Management of Parkinson Disease. Clinical Neuropharmacology 38:3, pages 89-103.
Crossref
Mustafa Varçin, Eduard Bentea, Steven Roosens, Yvette Michotte & Sophie Sarre. (2013) Involvement of CRH Receptors in the Neuroprotective Action of R-Apomorphine in the Striatal 6-OHDA Rat Model. Neuroscience and Medicine 04:04, pages 299-318.
Crossref
Koji Yamada, Noriaki Miyauchi & Tomoyuki Kanda. (2013) Subcutaneous apomorphine injection: rescue management of motor fluctuations associated with levodopa-therapy. Folia Pharmacologica Japonica 141:1, pages 44-51.
Crossref
J. Garcia‐Gavin, D. González‐Vilas, V. Fernández‐Redondo, L. Campano & J. Toribio. (2010) Allergic contact dermatitis caused by apomorphine hydrochloride in a carer. Contact Dermatitis 63:2, pages 112-115.
Crossref
P.A. LeWitt. 2010. Encyclopedia of Movement Disorders. Encyclopedia of Movement Disorders 332 337 .
David E. Nichols. 2010. The Dopamine Receptors. The Dopamine Receptors 75 99 .
O.K. Sujith & Carol Lane. (2009) Review: Therapeutic options for continuous dopaminergic stimulation in Parkinson's disease. Therapeutic Advances in Neurological Disorders 2:2, pages 105-113.
Crossref
Liming Luan, Feng Ding, Yi Ai, Anders Andersen, Peter Hardy, Eric Forman, Greg A. Gerhardt, Don M. Gash, Richard Grondin & Zhiming Zhang. (2008) Pharmacological MRI (phMRI) Monitoring of Treatment in Hemiparkinsonian Rhesus Monkeys. Cell Transplantation 17:4, pages 417-425.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.